临床实践指南:鼻出血(Epistaxis)
该多学科指南针对≥3岁、因鼻出血需医疗建议或治疗的患者,涵盖急诊、门诊、住院及远程场景。指南提出14条关键行动声明,包括初始接触时区分需紧急处理者、持续压迫鼻下1/3至少5分钟、压迫不能定位出血点时鼻腔填塞、疑似凝血障碍或使用抗凝/抗血小板药者用可吸收填塞物、 anterior rhinoscopy 找出血点、复发性或单侧复发性出血行鼻内镜、出血点明确者用局部血管收缩剂/烧灼/保湿剂、烧灼前麻醉且仅限出血或疑似出血点、填塞或烧灼不能控制者评估手术动脉结扎或血管内栓塞、无危及生命出血时先一线治疗再输血或逆转抗凝、复发性双侧鼻出血或家族史者评估鼻/口腔黏膜毛细血管扩张以诊断遗传性出血性毛细血管扩张症。
要点
- 初始接触时先区分需紧急处理的鼻出血患者与不需要者。
- 对需紧急处理的活动性出血,持续用力压迫鼻下1/3至少5分钟,可借助患者或照护者。
- 压迫仍不能定位出血点时行鼻腔填塞;疑似凝血障碍或用抗凝/抗血小板药者用可吸收填塞物。
- 复发性鼻出血经填塞或烧灼后仍出血、或复发性单侧鼻出血,行鼻内镜找出血点并指导后续处理。
- 无危及生命出血时,对使用抗凝/抗血小板药者先一线治疗,再考虑输血、逆转或停用抗凝/抗血小板药。
适用人群与场景
- 适用于年龄≥3岁、有鼻出血或鼻出血史且需要医疗治疗或寻求医疗建议的个体。
- 适用场景包括门诊医疗点、急诊科、住院医院以及电话和远程医疗等远程门诊接触。
- 目标受众包括家庭医学医师、内科医师、儿科医师、医师助理、执业护士等初级保健提供者,以及急诊医学提供者、耳鼻喉科医师、介入放射学/神经放射学和神经介入医师、血液科医师和心脏科医师等专科医师。
诊断标准与关键阈值
- 目标患者定义为鼻孔、鼻腔或鼻咽部出血足以需要医疗建议或医疗照护者,包括严重、持续和/或复发性出血以及影响生活质量的出血。
处置流程与药物剂量
- 初始接触时,临床医生应区分需要紧急处理的鼻出血患者与不需要紧急处理的患者。
- 对需要紧急处理的患者,临床医生应治疗活动性出血,方法为对鼻下1/3持续用力压迫5分钟或更长时间,可借助患者或照护者协助。
- 对于鼻部压迫后出血仍妨碍识别出血部位的患者,临床医生应治疗持续活动性出血,方法为鼻腔填塞。
- 对于疑似出血性疾病或正在使用抗凝或抗血小板药物的患者,临床医生应使用可吸收填塞物。
- 对于接受鼻腔填塞的患者,临床医生应教育患者填塞物类型、取出时机和计划(若不可吸收)、术后护理以及任何需要紧急重新评估的体征或症状。
- 对于任何鼻出血患者,临床医生应记录增加出血频率或严重程度的因素,包括个人或家族出血性疾病史、抗凝或抗血小板药物使用史或鼻内药物使用史。
- 对于鼻出血患者,临床医生应在去除任何血凝块(如有)后行前鼻镜检查以识别出血来源。
- 对于既往接受填塞或烧灼治疗后仍复发性鼻出血、或复发性单侧鼻出血的患者,临床医生应行或转诊至能行鼻内镜检查的临床医生,以识别出血部位并指导进一步处理。
红旗征与不能漏的情况
- 需要紧急处理的鼻出血患者(初始接触时需区分)。
- 鼻部压迫后出血仍妨碍识别出血部位。
- 疑似出血性疾病或正在使用抗凝或抗血小板药物。
- 复发性鼻出血经填塞或烧灼后仍出血,或复发性单侧鼻出血。
- 填塞或鼻腔烧灼不能控制的持续或复发性出血。
- 危及生命的出血(此时输血、逆转抗凝或停用抗凝/抗血小板药物的顺序不受先一线治疗限制)。
- 有复发性双侧鼻出血史或复发性鼻出血家族史(需评估遗传性出血性毛细血管扩张症)。
研究设计与关键结果
- 该指南为多学科临床实践指南,旨在识别鼻出血管理中的质量改进机会并制定清晰可操作的建议。
- 指南针对≥3岁、有鼻出血或鼻出血史且需要医疗治疗或寻求医疗建议的患者。
- 指南提出14条关键行动声明,涵盖诊断、治疗和预防鼻出血。
- 指南讨论一线治疗如鼻部压迫、局部血管收缩剂、鼻腔填塞和鼻腔烧灼。
- 指南还涉及更复杂的鼻出血管理,包括内镜下动脉结扎和介入放射学操作。
- 指南纳入遗传性出血性毛细血管扩张症患者和使用抑制凝血和/或血小板功能药物的患者两个特殊群体的管理选项。
- 指南指出鼻出血估计占所有急诊就诊的0.5%,占所有耳鼻喉科相关急诊就诊的比例高达三分之一。
- 指南指出严重鼻出血需住院积极治疗的比例报告为鼻出血患者的0.2%。
证据类型、等级与局限
- 证据类型:多学科临床实践指南。
- 指南旨在聚焦指南制定组认为最重要的循证质量改进机会,并非鼻出血管理的全面通用指南。
- 指南声明不意图限制或约束临床医生基于其经验和个体患者评估提供的照护。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急诊/ICU床旁应首先区分需紧急处理的鼻出血患者与不需要者。
- 对需紧急处理的活动性出血,立即持续压迫鼻下1/3至少5分钟,可借助患者或照护者。
- 压迫不能定位出血点时行鼻腔填塞;疑似出血性疾病或使用抗凝/抗血小板药物者选择可吸收填塞物。
- 鼻腔填塞后需教育患者填塞物类型、取出时机和计划(若不可吸收)、术后护理及需紧急重新评估的体征或症状。
- 对使用抗凝/抗血小板药物者,无危及生命出血时先一线治疗,再考虑输血、逆转抗凝或停用抗凝/抗血小板药物。
- 复发性鼻出血经填塞或烧灼后仍出血、或复发性单侧鼻出血,应行或转诊鼻内镜找出血点。
- 填塞或烧灼不能控制的持续或复发性出血,应评估或转诊手术动脉结扎或血管内栓塞。
- 对鼻出血难以控制或担心未识别病理者,可行或转诊鼻内镜检查鼻腔和鼻咽部(推荐级别为选项)。
指南或共识出处
- 指南名称:Clinical Practice Guideline: Nosebleed (Epistaxis)。
- 发布机构:Otolaryngol Head Neck Surg。
- 年份:原文未写明。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Nosebleed, also known as epistaxis, is a common problem that occurs at some point in at least 60% of people in the United States. While the majority of nosebleeds are limited in severity and duration, about 6% of people who experience nosebleeds will seek medical attention. For the purposes of this guideline, we define the target patient with a nosebleed as a patient with bleeding from the nostril, nasal cavity, or nasopharynx that is sufficient to warrant medical advice or care. This includes bleeding that is severe, persistent, and/or recurrent, as well as bleeding that impacts a patient's quality of life. Interventions for nosebleeds range from self-treatment and home remedies to more intensive procedural interventions in medical offices, emergency departments, hospitals, and operating rooms. Epistaxis has been estimated to account for 0.5% of all emergency department visits and up to one-third of all otolaryngology-related emergency department encounters. Inpatient hospitalization for aggressive treatment of severe nosebleeds has been reported in 0.2% of patients with nosebleeds.
PURPOSE: The primary purpose of this multidisciplinary guideline is to identify quality improvement opportunities in the management of nosebleeds and to create clear and actionable recommendations to implement these opportunities in clinical practice. Specific goals of this guideline are to promote best practices, reduce unjustified variations in care of patients with nosebleeds, improve health outcomes, and minimize the potential harms of nosebleeds or interventions to treat nosebleeds. The target patient for the guideline is any individual aged ≥3 years with a nosebleed or history of nosebleed who needs medical treatment or seeks medical advice. The target audience of this guideline is clinicians who evaluate and treat patients with nosebleed. This includes primary care providers such as family medicine physicians, internists, pediatricians, physician assistants, and nurse practitioners. It also includes specialists such as emergency medicine providers, otolaryngologists, interventional radiologists/neuroradiologists and neurointerventionalists, hematologists, and cardiologists. The setting for this guideline includes any site of evaluation and treatment for a patient with nosebleed, including ambulatory medical sites, the emergency department, the inpatient hospital, and even remote outpatient encounters with phone calls and telemedicine. Outcomes to be considered for patients with nosebleed include control of acute bleeding, prevention of recurrent episodes of nasal bleeding, complications of treatment modalities, and accuracy of diagnostic measures. This guideline addresses the diagnosis, treatment, and prevention of nosebleed. It focuses on nosebleeds that commonly present to clinicians via phone calls, office visits, and emergency room encounters. This guideline discusses first-line treatments such as nasal compression, application of vasoconstrictors, nasal packing, and nasal cautery. It also addresses more complex epistaxis management, which includes the use of endoscopic arterial ligation and interventional radiology procedures. Management options for 2 special groups of patients-patients with hereditary hemorrhagic telangiectasia syndrome and patients taking medications that inhibit coagulation and/or platelet function-are included in this guideline. This guideline is intended to focus on evidence-based quality improvement opportunities judged most important by the guideline development group. It is not intended to be a comprehensive, general guide for managing patients with nosebleed. In this context, the purpose is to define useful actions for clinicians, generalists, and specialists from a variety of disciplines to improve quality of care. Conversely, the statements in this guideline are not intended to limit or restrict care provided by clinicians based on their experience and assessment of individual patients.
ACTION STATEMENTS: The guideline development group made recommendations for the following key action statements: (1) At the time of initial contact, the clinician should distinguish the nosebleed patient who requires prompt management from the patient who does not. (2) The clinician should treat active bleeding for patients in need of prompt management with firm sustained compression to the lower third of the nose, with or without the assistance of the patient or caregiver, for 5 minutes or longer. (3a) For patients in whom bleeding precludes identification of a bleeding site despite nasal compression, the clinician should treat ongoing active bleeding with nasal packing. (3b) The clinician should use resorbable packing for patients with a suspected bleeding disorder or for patients who are using anticoagulation or antiplatelet medications. (4) The clinician should educate the patient who undergoes nasal packing about the type of packing placed, timing of and plan for removal of packing (if not resorbable), postprocedure care, and any signs or symptoms that would warrant prompt reassessment. (5) The clinician should document factors that increase the frequency or severity of bleeding for any patient with a nosebleed, including personal or family history of bleeding disorders, use of anticoagulant or antiplatelet medications, or intranasal drug use. (6) The clinician should perform anterior rhinoscopy to identify a source of bleeding after removal of any blood clot (if present) for patients with nosebleeds. (7a) The clinician should perform, or should refer to a clinician who can perform, nasal endoscopy to identify the site of bleeding and guide further management in patients with recurrent nasal bleeding, despite prior treatment with packing or cautery, or with recurrent unilateral nasal bleeding. (8) The clinician should treat patients with an identified site of bleeding with an appropriate intervention, which may include one or more of the following: topical vasoconstrictors, nasal cautery, and moisturizing or lubricating agents. (9) When nasal cautery is chosen for treatment, the clinician should anesthetize the bleeding site and restrict application of cautery only to the active or suspected site(s) of bleeding. (10) The clinician should evaluate, or refer to a clinician who can evaluate, candidacy for surgical arterial ligation or endovascular embolization for patients with persistent or recurrent bleeding not controlled by packing or nasal cauterization. (11) In the absence of life-threatening bleeding, the clinician should initiate first-line treatments prior to transfusion, reversal of anticoagulation, or withdrawal of anticoagulation/antiplatelet medications for patients using these medications. (12) The clinician should assess, or refer to a specialist who can assess, the presence of nasal telangiectasias and/or oral mucosal telangiectasias in patients who have a history of recurrent bilateral nosebleeds or a family history of recurrent nosebleeds to diagnose hereditary hemorrhagic telangiectasia syndrome. (13) The clinician should educate patients with nosebleeds and their caregivers about preventive measures for nosebleeds, home treatment for nosebleeds, and indications to seek additional medical care. (14) The clinician or designee should document the outcome of intervention within 30 days or document transition of care in patients who had a nosebleed treated with nonresorbable packing, surgery, or arterial ligation/embolization. The policy level for the following recommendation, about examination of the nasal cavity and nasopharynx using nasal endoscopy, was an option: (7b) The clinician may perform, or may refer to a clinician who can perform, nasal endoscopy to examine the nasal cavity and nasopharynx in patients with epistaxis that is difficult to control or when there is concern for unrecognized pathology contributing to epistaxis.
参考来源
- Tunkel DE, Anne S, Payne SC, et al. Clinical Practice Guideline: Nosebleed (Epistaxis). Otolaryngol Head Neck Surg. 2020. PMID: 31910111. doi:10.1177/0194599819890327
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。